Inozyme Pharma (INZY)
(Real Time Quote from BATS)
$5.13 USD
+0.15 (3.01%)
Updated Sep 9, 2024 02:06 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Inozyme Pharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 189 | 128 | 112 | 148 | 47 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 4 | 4 | 3 | 0 |
Total Current Assets | 196 | 131 | 115 | 151 | 47 |
Net Property & Equipment | 1 | 2 | 2 | 3 | 0 |
Investments & Advances | 0 | 0 | 0 | 13 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 4 | 3 | 3 | 0 |
Total Assets | 201 | 139 | 124 | 169 | 48 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 3 | 2 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 11 | 9 | 7 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 15 | 15 | 12 | 10 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 45 | 4 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 60 | 21 | 14 | 11 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 78 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 426 | 333 | 257 | 249 | 1 |
Retained Earnings | -286 | -215 | -148 | -91 | -35 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 140 | 118 | 109 | 158 | 45 |
Total Liabilities & Shareholder's Equity | 201 | 139 | 124 | 169 | 48 |
Total Common Equity | 140 | 118 | 109 | 158 | -33 |
Shares Outstanding | 61.70 | 40.30 | 23.60 | 23.30 | NA |
Book Value Per Share | 2.28 | 2.94 | 4.63 | 6.79 | 0.00 |
Fiscal Year End for Inozyme Pharma, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 145 | 166 | 189 | 192 | 140 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 8 | 8 | 8 | 3 |
Total Current Assets | 153 | 174 | 196 | 201 | 144 |
Net Property & Equipment | 1 | 1 | 1 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 2 | 2 | 4 |
Total Assets | 156 | 177 | 201 | 206 | 151 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 2 | 1 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 9 | 13 | 9 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 16 | 12 | 15 | 12 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 45 | 45 | 45 | 32 | 32 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 61 | 58 | 60 | 45 | 45 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 431 | 428 | 426 | 425 | 353 |
Retained Earnings | -336 | -309 | -286 | -264 | -248 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 94 | 119 | 140 | 160 | 106 |
Total Liabilities & Shareholder's Equity | 156 | 177 | 201 | 206 | 151 |
Total Common Equity | 94 | 119 | 140 | 160 | 106 |
Shares Outstanding | 62.70 | 61.80 | 61.70 | 61.70 | 58.80 |
Book Value Per Share | 1.51 | 1.92 | 2.28 | 2.60 | 1.80 |